Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

BACKGROUND: PIK3CA contributes to cell growth via the PI3K-AKT-mammalian target of rapamycin (mTOR) signaling pathway. Mutations in the pathway are frequently observed in solid tumors. We assessed the efficacy and safety of sirolimus, an mTOR inhibitor, in chemotherapy-refractory solid tumors with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Byeon, Seonggyu, Kang, Myoung Joo, Choi, Yoon Ji, Kim, Yu Jung, Kim, Miso, Yun, Jina, Yi, Seong Yoon, Kim, Jin Young, Kim, Seung Tae, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798137/
https://www.ncbi.nlm.nih.gov/pubmed/35117688
http://dx.doi.org/10.21037/tcr.2020.04.07

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798137/
https://www.ncbi.nlm.nih.gov/pubmed/35117688
http://dx.doi.org/10.21037/tcr.2020.04.07

Ejemplares similares